Tetraphase shares unchanged on first day of trading after $75 million IPO

Tetraphase Pharmaceuticals Inc. stock closed unchanged at $7 a share on its first day of trading Wednesday after the Watertown biotechnology start-up raised $74.9 million in an IPO.

Tetraphase, which is working on technology to create antibiotics for abdominal and urinary tract infections, priced its offering of 10.7 million shares of common stock at $7 a share. That was below the $10 to $12 price range initially specified in the company’s registration statement.


Another Watertown biotechnology company, Enanta Pharmaceuticals Inc., priced 4 million shares at $14 per share Wednesday in what would be a $56 million IPO. Enanta, which is developing drugs to treat the hepatitis C virus, will begin trading Thursday.

Robert Weisman

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of